why is vcr to receive nickels and dimes.
You see they have a problem there are clinical costs and this device requires a full blown heart transplant surgery and staff.
In the US, the whole procedure is reimbursed under what’s called a Diagnosis
Related Group 103 which pays for the hospital costs and the costs of the product in
the amount of US$130,000 to US$160,000, depending on the State where the
hospital is based.
Unfortunately, medical costs are increasing worldwide, so we may find pressure
on the product price as more of the total reimbursement is consumed by the
hospital and clinical costs. A similar DRG mechanism exists in most developed
countries.
As Ventracor says :
we’ll need to work closely with our clinical partners to find ways to
minimise total costs so that we can maintain the payments paid to us. For example,
we might design a device or make improvements so that it would be easier to
implant and follow up, which could result in lower clinical costs. That way, we
could maintain or even expand our proportion of the total reimbursement.
- Forums
- ASX - By Stock
- VCR
- vcr stock to watch
VCR
ventracor limited
vcr stock to watch, page-27
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)